The report will be delivered in 2-3 business days.

COVID-19 Drug Associated APIs Global Market Report 2021: COVID-19 Growth And Change To 2030

Starting Price : $5000 | Pages : 175 | Published : March 2021 | SKU CODE : 7645 | Format :


The COVID-19 drug-associated APIs market consists of sales of active pharmaceutical ingredients used in the manufacturing of COVID-19 drugs. The active pharmaceutical ingredients are chemicals which are responsible for pharmacological activity in the human body and are used as a base in pharmaceutical drug or medicine. The APIs used for the preparation of COVID-19 drugs and include Azithromycin, Fentanyl, Albuterol, Cisatracurium and others.

The COVID-19 drug-associated APIs market covered in this report is segmented by drug class into antimalarials, bronchodilators, antibiotics, antivirals, others.

The global COVID-19 drug associated apis market is expected to grow from $4.73 billion in 2020 to $5.09 billion in 2021 at a compound annual growth rate (CAGR) of 7.6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The COVID-19 drug-associated APIs market is expected to reach $6.66 billion in 2025 at a CAGR of 7%.

High demand for some antiretrovirals, antimalarials, sedatives, bronchodilators, and other respiratory drugs drives the demand for the active pharmaceutical ingredients (APIs) used in the production of COVID-19 drugs. Active pharmaceutical ingredients (APIs) are the biologically active component used in manufacturing pharmaceutical drugs. Remdesivir and Favipiravir are two common antiviral medications used currently for the treatment of COVID-19 patients. Remdesivir is a medication approved for emergency use in the USA and Japan for the treatment of COVID-19 patients. Remdesivir gained emergency use authorization (EUA) from the FDA on May 1, 2020, based on its preliminary data showing a faster time to recovery in hospitalized patients with several diseases. Favipiravir, which used to treat influenza in Japan, has also shown a positive effect on COVID patients. As COVID-19 is a respiratory ailment, the demand for bronchodilators spiked significantly. Therefore, the increasing demand for antivirals, antimalarials, and bronchodilators is projected to boost the demand for COVID-19 associated drug APIs market over the forecast period.

The disruptions caused by the COVID-19 outbreak in the supply chain of medical products limited the growth of the COVID-19 drug-associated APIs market in the past few months. The source for APIs plays a crucial part in the strategic plan to combat the COVID-19 pandemic. The majority of APIs for generic drug manufacturing across the globe are sourced from India, with nearly 30% generic APIs used in the USA. The restrictions imposed on the export of pharma products owing to COVID-19 supply chain disruptions restricted the market growth. For instance, India imposed an export ban on 26 pharma products and medical devices in March 2020. The ban was imposed attributing to the supply chain disruptions on API and other bulk drugs due to restrictive measures such as lockdown and closure of factories in many countries across the globe to ensure that the disease spread is contained. Thus, shortages caused by the disruptions in supply chains and restrictions imposed on the export of pharma products impacted the growth of the COVID-19 drug-associated APIs market over the last few months.

Key players operating in the pharmaceutical industry that manufactures COVID-19 drug associated APIs are focusing on strategies such as plant capacity or production capacity expansion to meet the increasing demand due to the rising number of coronavirus cases across the globe. For instance, in March 2020, Alembic Pharmaceuticals Ltd announced that the company is ramping up the production for the company’s production for azithromycin to 20 tons per month. Likewise, In April 2020, FUJIFILM Corporation announced the expansion of its manufacturing capacity and increase in the production of influenza antiviral Avigan Tablet (Favipiravir) by nearly 2.5 times by the end of July. Avigan is currently undergoing clinical trials testing its safety and efficacy for the treatment of COVID-19 patients.

In February 2020, Dr. Reddy Labs announced the acquisition of the branded generics business of Wockhardt for an amount of $242 million (INR 1,850 crore). The acquisition is expected to scale-up the former company’s presence in home markets including India, Nepal, Sri Lanka, Bhutan, and the Maldives. The Wockhardt business consists of a product portfolio of 62 brands and in multiple therapy fields such as dermatology, neurology, respiratory, VMS, pain, gastroenterology, and vaccine. Wockhardt Ltd. was founded in 1999 and is a global biotechnology and pharmaceutical company based in Mumbai, India.

Major players in the COVID-19 drug-associated APIs market are Dr. Reddy's Laboratories, Lianyungang Guike Pharmaceutical, Alembic Pharmaceutical, Wockhardt Ltd, Sandoz Srl, Lupin Limited, Aurobindo Pharma Ltd., Shanghai Shyndec Pharmaceutical (Haimen) Co Ltd, and Yatai Pharma.

The regions covered in the COVID-19 drug-associated APIs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the COVID-19 drug-associated APIs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The global COVID-19 drug-associated APIs market is segmented -

1) By Drug Class: Antimalarials, Bronchodilators, Antibiotics, Antivirals, Others

    1. Executive Summary

    2. COVID-19 Drug Associated APIs Market Characteristics

    3. COVID-19 Drug Associated APIs Market Trends And Strategies

    4. Impact Of COVID-19 On COVID-19 Drug Associated APIs

    5. COVID-19 Drug Associated APIs Market Size And Growth

    5.1. Global COVID-19 Drug Associated APIs Historic Market, 2015-2020, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global COVID-19 Drug Associated APIs Forecast Market, 2020-2025F, 2030F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. COVID-19 Drug Associated APIs Market Segmentation

    6.1. Global COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    Antimalarials

    Bronchodilators

    Antibiotics

    Antivirals

    Others

    7. COVID-19 Drug Associated APIs Market Regional And Country Analysis

    7.1. Global COVID-19 Drug Associated APIs Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    7.2. Global COVID-19 Drug Associated APIs Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    8. Asia-Pacific COVID-19 Drug Associated APIs Market

    8.1. Asia-Pacific COVID-19 Drug Associated APIs Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    9. China COVID-19 Drug Associated APIs Market

    9.1. China COVID-19 Drug Associated APIs Market Overview

    9.2. China COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion

    10. India COVID-19 Drug Associated APIs Market

    10.1. India COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    11. Japan COVID-19 Drug Associated APIs Market

    11.1. Japan COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    12. Australia COVID-19 Drug Associated APIs Market

    12.1. Australia COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    13. Indonesia COVID-19 Drug Associated APIs Market

    13.1. Indonesia COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    14. South Korea COVID-19 Drug Associated APIs Market

    14.1. South Korea COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    15. Western Europe COVID-19 Drug Associated APIs Market

    15.1. Western Europe COVID-19 Drug Associated APIs Market Overview

    15.2. Western Europe COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    16. UK COVID-19 Drug Associated APIs Market

    16.1. UK COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    17. Germany COVID-19 Drug Associated APIs Market

    17.1. Germany COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    18. France COVID-19 Drug Associated APIs Market

    18.3. France COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    19. Eastern Europe COVID-19 Drug Associated APIs Market

    19.1. Eastern Europe COVID-19 Drug Associated APIs Market Overview

    19.2. Eastern Europe COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    20. Russia COVID-19 Drug Associated APIs Market

    20.1. Russia COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    21. North America COVID-19 Drug Associated APIs Market

    21.1. North America COVID-19 Drug Associated APIs Market Overview

    21.2. North America COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    22. USA COVID-19 Drug Associated APIs Market

    22.1. USA COVID-19 Drug Associated APIs Market Overview

    22.2. USA COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    23. South America COVID-19 Drug Associated APIs Market

    23.1. South America COVID-19 Drug Associated APIs Market Overview

    23.2. South America COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    24. Brazil COVID-19 Drug Associated APIs Market

    24.1. Brazil COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    25. Middle East COVID-19 Drug Associated APIs Market

    25.1. Middle East COVID-19 Drug Associated APIs Market Overview

    25.2. Middle East COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    26. Africa COVID-19 Drug Associated APIs Market

    26.1. Africa COVID-19 Drug Associated APIs Market Overview

    26.2. Africa COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    27. COVID-19 Drug Associated APIs Market Competitive Landscape And Company Profiles

    27.1. COVID-19 Drug Associated APIs Market Competitive Landscape

    27.2. COVID-19 Drug Associated APIs Market Company Profiles

    27.2.1. Dr. Reddy's Laboratories

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. Lianyungang Guike Pharmaceutical

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. Alembic Pharmaceutical

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. Wockhardt Ltd

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. Sandoz Srl

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. COVID-19 Drug Associated APIs Pipeline Analysis

    29. Key Mergers And Acquisitions In The COVID-19 Drug Associated APIs Market

    30. COVID-19 Drug Associated APIs Market Future Outlook and Potential Analysis

    31. Appendix

    31.1. Abbreviations

    31.2. Currencies

    31.3. Research Inquiries

    31.4. The Business Research Company

    31.5. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2015-2020, $ Billion
  • Table 2: Global Forecast Market Growth, 2020-2025F, 2030F, $ Billion
  • Table 3: Global COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 4: Global COVID-19 Drug Associated APIs Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 5: Global COVID-19 Drug Associated APIs Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 6: Asia-Pacific, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 7: China, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 8: India, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 9: Japan, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 10: Australia, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 11: Indonesia, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 12: South Korea, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 13: Western Europe, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 14: UK, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 15: Germany, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 16: France, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 17: Eastern Europe, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 18: Russia, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 19: North America, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 20: USA, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 21: South America, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 22: Brazil, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 23: Middle East, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 24: Africa, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 25: Dr. Reddy's Laboratories Financial Performance
  • Table 26: Lianyungang Guike Pharmaceutical Financial Performance
  • Table 27: Alembic Pharmaceutical Financial Performance
  • Table 28: Wockhardt Ltd Financial Performance
  • Table 29: Sandoz Srl Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2015-2020, $ Billion
  • Figure 2: Global Forecast Market Growth, 2020-2025F, 2030F, $ Billion
  • Figure 3: Global COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 4: Global COVID-19 Drug Associated APIs Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 5: Global COVID-19 Drug Associated APIs Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 6: Asia-Pacific, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 7: China, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 8: India, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 9: Japan, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 10: Australia, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 11: Indonesia, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 12: South Korea, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 13: Western Europe, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 14: UK, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 15: Germany, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 16: France, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 17: Eastern Europe, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 18: Russia, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 19: North America, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 20: USA, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 21: South America, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 22: Brazil, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 23: Middle East, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 24: Africa, COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 25: Dr. Reddy's Laboratories Financial Performance
  • Figure 26: Lianyungang Guike Pharmaceutical Financial Performance
  • Figure 27: Alembic Pharmaceutical Financial Performance
  • Figure 28: Wockhardt Ltd Financial Performance
  • Figure 29: Sandoz Srl Financial Performance
Global Cancer Monoclonal Antibodies Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Clinical Nutrition Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Cervical Cancer Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Central Nervous System Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Checkpoint Inhibitors Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Cell Therapy Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Cell Culture Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Cell And Gene Therapy Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Generic Pharmaceuticals Global Market Report 2021: COVID-19 Growth And Change To 2030
View Report
Pharmaceutical Drugs Market - By Segments (Musculoskeletal Disorders Drugs, Cardiovascular Drugs, Oncology Drugs, Anti-Infective Drugs, Metabolic Disorder Drugs, Central Nervous System Drugs, Genito-Urinary Drugs, Respiratory Diseases Drugs, Gastrointestinal Drugs, Hematology Drugs, Dermatology Drugs, Ophthalmology Drugs), And By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
Antiemetics And Antinauseants Global Market Report 2021: COVID 19 Impact and Recovery to 2030
View Report
Antifungals Global Market Report 2021: COVID 19 Impact and Recovery to 2030
View Report
Pharmaceutical Drugs And Biologics Logistics Market - By Type Of Service (Cold Chain Logistics, Non-Cold Chain Logistics), By Mode Of Transport (Air Transportation, Ocean Transportation, Land Transportation), By Pharmaceutical Type (Pharmaceutical Drugs, Biologics), By Therapeutic Area (Metabolic Disorders Drugs, Anti-Infective Drugs, Central Nervous System Drugs, Respiratory Diseases Drugs, Cardiovascular Drugs, Musculoskeletal Disorders Drugs, Oncology Drugs, Hematology Drugs, Monoclonal Antibodies (MAbS), Genito-Urinary Drugs, Gastrointestinal Drugs, Therapeutic Proteins, Dermatology Drugs, Vaccines, Ophthalmology Drugs), And By Region, Opportunities And Strategies - Global Forecast To 2030
View Report
Diabetes Therapies Market - By Segments (Injectables And Oral), Trends, Key Players, Opportunities And Strategies – Global Forecast To 2023
View Report
Global Biologics Market - By Type (Monoclonal Antibodies, Therapeutic Proteins, Vaccines), By Route Of Administration (Oral, Others (IV or IP)), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription Drugs, OTC Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And By Region, Opportunities And Strategies – Global Forecast To 2023
View Report
Pharmaceuticals Market - By Type (Pharmaceutical Drugs, Biologics), By Type Of Pharmaceutical Drugs (Cardiovascular Drugs, Dermatology Drugs, Gastrointestinal Drugs, Genito-Urinary Drugs, Hematology Drugs, Anti-Infective Drugs, Metabolic Disorder Drugs, Musculoskeletal Disorder Drugs, Central Nervous System Drugs, Oncology Drugs, Ophthalmology Drugs, Respiratory Diseases Drugs), By Type Of Biologics Drugs (Monoclonal Antibodies (MAbS), Therapeutic Proteins, Vaccines), And By Region, Opportunities And Strategies – Global Forecast To 2030
View Report

Call Us

+1 3156230293

(Americas)

+44 2071930708

(Europe)

+91 8897263534

(Asia & Others)